Hospital IQ Expands Reach of Operational Excellence Technology with Siemens Healthineers

2 years ago

Collaboration scales enterprise-wide value creation amid industry shift towards value-based care NEWTON, Mass.--(BUSINESS WIRE)--#healthcare--Hospital IQ, the leading predictive hospital operations…

Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells

2 years ago

Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…

Inogen Announces CFO Transition Plan

2 years ago

– Names Mike Sergesketter as Interim Chief Financial Officer – GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company…

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

2 years ago

FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing…

New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium

2 years ago

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in Anesthesia & Analgesia in which…

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

2 years ago

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual…

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

2 years ago

-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS…

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

2 years ago

U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948…

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

2 years ago

Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients…

19e Guignolée Dr Julien Tous les enfants ont le droit de grandir en santé !

2 years ago

Premier bilan partiel de 1 300 000 $ recueillis, en date du 11 décembre 2021 Guignolée Dr Julien 11 décembre…